Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Argent BiopharmaRGTLF 3-Year Share Buyback Ratio is -204.10 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 646 Drug Manufacturers companies, Argent Biopharma ranks worse than 98.3% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Argent Biopharma's current 3-Year Share Buyback Ratio was -204.10%.
The historical rank and industry rank for Argent Biopharma's 3-Year Share Buyback Ratio or its related term are showing as below:
RGTLF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -204.1 Med: -47.9 Max: -4
Current: -204.1
During the past 13 years, Argent Biopharma's highest 3-Year Share Buyback Ratio was -4.00%. The lowest was -204.10%. And the median was -47.90%.
RGTLF's 3-Year Share Buyback Ratio is ranked worse than 98.3% of 646
companies
in the Drug Manufacturers industry
Industry Median: -1.9
vs RGTLF: -204.10
Argent Biopharma (OTCPK:RGTLF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Argent Biopharma 3-Year Share Buyback Ratio Related Terms
RGTLF vs ZTS: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's 3-Year Share Buyback Ratio falls into.
Argent Biopharma 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -204.10 mean?
Argent Biopharma (RGTLF) has a 3-Year Share Buyback Ratio of -204.10 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Argent Biopharma and its competitors. According to the industry distribution chart, Argent Biopharma ranks #635 out of 646 companies in the Drug Manufacturers industry, placing it in the top 98.3%.
Is Argent Biopharma's 3-Year Share Buyback Ratio too high?
Argent Biopharma's current 3-Year Share Buyback Ratio is -204.10. Based on the distribution chart, Argent Biopharma ranks #635 out of 646 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Argent Biopharma's 3-Year Share Buyback Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #635 out of 646 companies for 3-Year Share Buyback Ratio. This places Argent Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Argent Biopharma and its competitors. Argent Biopharma's current 3-Year Share Buyback Ratio is -204.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.03 — trading 150% above its estimated fair value. The current 3-Year Share Buyback Ratio is -204.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current 3-Year Share Buyback Ratio is -204.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 
